Immunic Reports Positive Interim Data from Phase 2 CALLIPER

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Switzerland , Russia , Ukraine , United States , America , Andreas Muehler , Daniel Vitt , Jens Kuhle , Jessica Breu , Edna Kaplan , Paula Schwartz , Rx Communications Group , Sclerosis Centre , University Hospital Basel , Nasdaq , Prnewswire Immunic Inc Nasdaq , Program In Relapsing Multiple Sclerosis Ongoing , Exchange Commission , Immunic Inc , Week Data , First Half , Patients Shows Improvements , Consistent Throughout , Overall Progressive Multiple Sclerosis Population , All Subtypes , Nfl Effect , Neuroprotective Potential , Brain Volume Data , Cohort Expected , Relapsing Multiple Sclerosis Ongoing , Conference Call , Held Tomorrow , Senior Physician , Neuroimmunology Unit , Multiple Sclerosis Centre , Chief Executive Officer , Chief Medical Officer , North America , Vidofludimus Calcium , Private Securities Litigation Reform Act , Annual Report , Investor Relations ,